Publicaciones
-
Santa-María López V, Felip-Badia A, Marina Caballero Bellón, Sanchez-Sierra N, Castañeda-Heredia A, Garraus-Oneca M, Gorostegui M, Simão-Rafael M, Muñoz JP, Pérez-Somarriba M, Mañe S, Planells MC, Pérez-Jaume S and Mora J.
Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio-Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse
PEDIATRIC BLOOD & CANCER . 73(4): .
-
Sentís I, Melero JL, Cebrià A, Grzelak M, Soto M, Michel A, Rovira Q, Rodriguez-Hernandez CJ, Caratù G, Urpi A, Sauvage C, Mendizabal-Sasieta A, Maspero D, Lavarino C, Pascual-Reguant A, Castañeda-Heredia A, Muñoz Perez JP, Mora J, Harari A, Nieto JC, Avgustinova A and Heyn H.
Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer
ANNALS OF ONCOLOGY . 36(9): 1096-1106.
-
Cristina Larrosa Espinosa, Simao-Rafael M, Salvador-Marcos N, Muñoz JP, Lavarino C, Chantada G and Mora J.
Case Report: Successful treatment of metastatic retinoblastoma with CNS involvement with anti-GD2 immunotherapy, intrathecal topotecan and reduced systemic chemotherapy
Frontiers in Pediatrics . 12: 1509645-1509645. Nº de citas: 4
-
Planas-Roman S, Salvador-Marcos N, Lavarino C, Zuccarino F, Pereda D, Muñoz JP and Aurensanz E.
Hamartoma of mature cardiac myocytes presenting as a polypoid epicardial tumor in the interatrial groove and with gene fusions by copy number anomalies of chromosome 7
CARDIOVASCULAR PATHOLOGY . 73: 107660-107660. Nº de citas: 2
-
Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK.
Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects
Frontiers in Oncology . 14: 1380917-1380917. Nº de citas: 3
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de citas: 4
